Compare Biogen Inc (BIIB) vs First Solar, Inc. (FSLR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs First Solar, Inc. — how do they compare? Biogen Inc trades at $210.65 (market cap $30.86B), while First Solar, Inc. trades at $224.56 (market cap $25.89B). The key difference: Biogen Inc is the larger of the two by market cap, and Biogen Inc is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals.
| BIIB | FSLR | |
|---|---|---|
Market Cap | $30.86B | $25.89B |
Sector | Health | Technology |
52-Week High | $216.63 | $318.30 |
52-Week Low | $132.22 | $180.05 |
Enterprise Value | $37.93B | $24.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $210.65, up 3.32% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 37.1 and net income margin of 8.32%, supported by positive cash flow trends. Recent news highlights the acquisition of RayThera Inc. and raised 2026 guidance, reflecting strategic growth initiatives.
Outlook is positive with analyst consensus price target of $234.47, though risks include competitive pressures and earnings volatility. Investment opportunity lies in pipeline expansion and Alzheimer's drug traction, balanced by margin compression concerns from legacy MS portfolio declines.
First Solar (FSLR) trades at $223.69, down 7.15% amid a class action lawsuit alleging securities fraud from February 2025 to February 2026. Technically, the stock is bearish with support at $215 and resistance at $228. Fundamentally, revenue grew to $5.22B in 2025 with a net income margin of 29.27%, though Q4 2025 EPS missed expectations. Analyst consensus is bullish with a $282.07 price target, but legal risks cloud near-term sentiment.
The outlook is mixed: strong profitability and growth support upside, but the lawsuit and bearish technicals pose risks. Investors should weigh robust fundamentals against legal uncertainties and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →
